{
    "clinical_study": {
        "@rank": "16682", 
        "arm_group": {
            "arm_group_label": "Vantictumab combined with paclitaxel", 
            "arm_group_type": "Experimental", 
            "description": "Drug: vantictumab combined with paclitaxel - administered intravenously"
        }, 
        "brief_summary": {
            "textblock": "This is an open-label Phase 1b dose-escalation study to assess the safety, tolerability, and\n      PK of vantictumab when combined with paclitaxel."
        }, 
        "brief_title": "A Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Locally Recurrent or Metastatic Breast Cancer", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Metastatic Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "Once the maximum tolerated dose (MTD) or maximum administered dose (MAD) has been\n      determined, up to 10 patients may be enrolled in the cohort-expansion phase to better\n      characterize the safety, tolerability and PK of vantictumab combined with paclitaxel. Up to\n      approximately 34 patients may be enrolled into the study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Signed Informed Consent Form\n\n          -  Age \u226518 years\n\n          -  Histologically documented adenocarcinoma of the breast with locally recurrent or\n             metastatic disease\n\n             o Patients with breast cancer overexpressing HER2 are not eligible.\n\n          -  Availability of tumor tissue, either archival FFPE or obtained at study entry through\n             fresh biopsy\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n\n          -  All acute treatment-related toxicity from prior therapy must have resolved to Grade \u2264\n             1 prior to study entry\n\n          -  Adequate hematologic and end-organ function\n\n          -  Evaluable or measurable disease per RECIST v1.1\n\n          -  For women of childbearing potential, agreement to use two effective forms of\n             contraception\n\n        Exclusion Criteria:\n\n          -  Known significant dose delays during prior treatment with a taxane due to\n             drug-related toxicities\n\n          -  Prior treatment with more than two regimens of systemic cytotoxic chemotherapy for\n             locally recurrent or metastatic disease\n\n          -  Treatment with any anti-cancer therapy within 3 weeks prior to initiation of study\n             treatment"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "34", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01973309", 
            "org_study_id": "18R5-002"
        }, 
        "intervention": {
            "arm_group_label": "Vantictumab combined with paclitaxel", 
            "description": "Vantictumab combined with paclitaxel will be administered IV.", 
            "intervention_name": "Vantictumab  combined with paclitaxel", 
            "intervention_type": "Drug", 
            "other_name": "(OMP-18R5)"
        }, 
        "intervention_browse": {
            "mesh_term": "Paclitaxel"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Locally Recurrent", 
            "Metastatic Breast Cancer"
        ], 
        "lastchanged_date": "March 19, 2014", 
        "location": [
            {
                "contact": {
                    "email": "monica.mita@cshs.org", 
                    "last_name": "Monica Mita, MD", 
                    "phone": "310-248-6729"
                }, 
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90048"
                    }, 
                    "name": "Cedars-Sinai Medical Center/ Samuel Oschin Comprehensive Cancer Institute"
                }, 
                "investigator": {
                    "last_name": "Monica Mita, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Crystal.ross@mckesson.com", 
                    "last_name": "Crystal Ross, BS, CCRP", 
                    "phone": "281-863-4630"
                }, 
                "contact_backup": {
                    "email": "Muhammad.khan@mckesson.com", 
                    "last_name": "Muhammad Khan, MD", 
                    "phone": "281-863-6538"
                }, 
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75246"
                    }, 
                    "name": "Texas Oncology-Baylor Charles A. Sammons Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Carlos H Becerra, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Donald A Richards, MD", 
                    "phone": "903-579-9800"
                }, 
                "facility": {
                    "address": {
                        "city": "Tyler", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75702"
                    }, 
                    "name": "Texas Oncology-Tyler"
                }, 
                "investigator": {
                    "last_name": "Donald A Richards, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1b Dose Escalation Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Breast Cancer", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The maximum tolerated dose (MTD) will be determined in patients treated with vantictumab in combination with paclitaxel", 
            "measure": "Safety and tolerability of vantictumab in combination with paclitaxel in patients with locally recurrent or metastatic breast cancer", 
            "safety_issue": "Yes", 
            "time_frame": "Subjects will be treated and observed for DLT through the end of the first cycle (Days 0-28 days)."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01973309"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Apparent half life, AUC, clearance, volume of distribution", 
            "measure": "Pharmacokinetics (PK) of vantictumab when administered in combination with paclitaxel to patients with locally recurrent or metastatic breast cancer", 
            "safety_issue": "Yes", 
            "time_frame": "Plasma sample for Pharmacokinetics (PK) analysis to be obtained prior to the vantictumab infusion on Days 0, 14, 56 and 70 and at the end of the  vantictumab infusion with paclitaxel infusion on Days 0 and 56."
        }, 
        "source": "OncoMed Pharmaceuticals, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "OncoMed Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}